Hikma Eyes Return To Growth After Further Cutting Generics Forecasts
Injectables And Branded Increases Offset 18% Sales Slide For Generics Unit In First Half
Hikma has once again downgraded its expectations for its generics business in 2022 as it revealed a first-half drop of 18% in sales for the unit. However, injectables and branded increases helped to offset the decline, while the company maintained that generics growth was on the horizon in 2023.
You may also be interested in...
Hikma and Adalvo have struck a licensing deal that will see Hikma commercialize a “high value” nasal spray treatment for allergic rhinitis in the MENA region.
Hikma and Glenmark have announced the long-awaited launch of the Ryaltris nasal spray on which the two companies have partnered in the US.
Siggi Olafsson has taken the reins at Mallinckrodt after stepping down as Hikma’s CEO. At the same time, Teva has named a new global R&D and chief medical officer while Piramal Pharma Solutions has appointed a fresh COO and Formycon has added to its supervisory board.